Article Text

Download PDFPDF
Fast-track FDA drug approvals and safety warnings

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To ensure that patients have more timely access to new and innovative medicines, regulatory bodies such as the European Medicines Agency (EMA) and the USA Food and Drug Administration (FDA), have developed a range of accelerated approval pathways.1 For such abbreviated development processes, drugs may be approved after a single phase II trial or using surrogate measures rather than actual clinical outcomes.1,2 In general, trials of drugs that have been through accelerated approval pathways involve relatively small numbers of patients and less …

View Full Text